Abstract: Compounds, compositions and method of using these compounds are disclosed for treating a disease or disorder in which it is desirable to inhibit BAX, such as a cardiovascular disease or disorder.

Abstract: A method for revitalizing mesenchymal stem cells (MSC) maintained in culture by transducing the MSC with vectors encoding a specific gene combination, as well as methods of use of MSC so revitalized in co-culturing hematopoietic stem cells.

Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD- L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.

Abstract: This disclosure provides novel compounds and methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as compounds and methods for treating or preventing BAX-mediated disorders.

Abstract: Microvesicles produced by stem cells grown on a silk scaffold for enhancing stem cell self-renewal/proliferation and promoting tenogenesis in damaged tendons, and their use in tendon wound repair and tendinopathy treatment. Also provided are compositions containing the microvesicles and devices for obtaining them.

Abstract: Persistence and linking of analytic products is provided. Information regarding a plurality of analytic methods is collected. A first process node is generated in a network. The first process node corresponds to a first analytic method. Information is collected regarding a plurality of executions of the first analytic method. A plurality of session nodes is generated in the network corresponding to the plurality of executions. Each of the plurality of session nodes is linked to the first process node. Metadata regarding the plurality of executions is associated with the plurality of session nodes. At least one product node is generated corresponding to a product. The product integrates a result value of at least one of the plurality of executions. The at least one product node is linked to the session node of the plurality of session nodes corresponding to the at least one of the plurality of executions.

Abstract: Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. Certain compounds and salts of Formula I are active as CMA modulators. The disclosure provides pharmaceutical compositions containing a compound of Formula I.

Abstract: Provided are high affinity Mycobacterium tuberculosis capsule-specific antibodies and fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments.

Abstract: Activators of mitofusins and their uses in treatment of diseases and disorders are disclosed.

Abstract: A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.

Abstract: A composition and a kit comprising a nitrite source admixed with a gelling agent for nitric oxide production. Also disclosed is a method for generating nitric oxide, which finds applications in the treatment of various diseases.

Abstract: A device for generating nitric oxide is disclosed. The device is configured for applying to either a body cavity or a surface of a subject in need thereof. Also disclosed is a method for the treatment of diseases or conditions with the device.

Abstract: An RNA tagging system for visualization of single mRNA molecules based on a MSB-MCP system, as well as methods of use.

Abstract: Methods are provided for identifying an agent that directly modulates a Bcl-2-associated x-protein (BAX) by promoting or disrupting dimerization of the BAX. Agents that directly modulate BAX by affecting dimerization are also provided.

Abstract: A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.

Abstract: Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.

Abstract: Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the proteins encoded by these genes bind to each other and are transported into the nucleus to form nuclear foci and initiate homologous recombination. Flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in BRCA1 or other DSB repair genes disrupted the binding of BRCA1 to its protein partners, the phosphorylation of p53 or the transport of the BRCA1complex to the nucleus in response to DNA damage. Each of these assays distinguished high-risk BRCA1 mutations from low-risk BRCA1 controls. Mutations in other DSB repair pathway genes produced molecular phenocopies with these assays. FVA assays may represent an adjunct to sequencing for categorizing VUS or may represent a stand-alone measure for assessing breast cancer risk.

Abstract: Methods and devices are disclosed for intra-operative viewing of pre- and intra-operative 3D patient images.

Abstract: Small molecule agonists of the pregnane X receptor (PXR), compositions and methods are disclosed for treating or preventing gut barrier dysfunction, an illness associated with gut barrier dysfunction, toxic or inflammatory injury to intestines, or leaky intestinal (gut) syndrome in a subject.

Abstract: Methods are provided for using 3-OH-kynurenamine to treat and prevent an inflammatory or autoimmune disease or disorder or transplant rejection, and for promoting immune tolerance.